中国P站

Xenotransplantation; Porcine heart; Immune rejection; Hyperacute rejection; Genetic engineering; Immunosuppression; Cross-species transplantation; Cardiac xenografts; Organ shortage; Future directions

Introduction

The persistent shortage of suitable human donor organs for heart transplantation has prompted the exploration of xenotransplantation, specifically the use of porcine (pig) hearts, as an alternative solution. With an increasing burden of end-stage heart failure and long transplant waiting lists, xenotransplantation presents a revolutionary approach to address the organ demand-supply gap [1-5]. Among various animal models, pigs are considered the most practical source due to their physiological compatibility, short gestation, and ease of genetic modification. However, despite major progress, porcine-to-human heart transplantation remains challenged by complex immunologic barriers, including hyperacute and acute vascular rejection, chronic immune activation, and the risk of cross-species pathogen transmission. This article discusses the key immunological challenges of porcine-to-human heart xenotransplantation, the current strategies to overcome them, and the future direction of the field [6-10].

Discussion

The immunologic response to porcine xenografts is far more vigorous than that seen in allotransplantation due to phylogenetic distance, leading to immediate and robust innate and adaptive immune reactions. One of the most formidable hurdles is hyperacute rejection (HAR), which occurs within minutes to hours after transplantation and is primarily mediated by preformed human natural antibodies against the α-Gal epitope expressed on porcine endothelial cells. This leads to complement activation, endothelial injury, thrombosis, and graft failure.

To address HAR, genetically modified pigs lacking the α-1,3-galactosyltransferase (GTKO pigs) have been developed, resulting in significantly reduced incidence of HAR. Additionally, pigs have been engineered to express human complement-regulatory proteins (e.g., CD46, CD55) and anticoagulant genes (e.g., thrombomodulin, EPCR), which enhance graft resistance to immune-mediated injury.

Beyond HAR, acute humoral xenograft rejection (AHXR) and cell-mediated rejection remain substantial obstacles. AHXR is triggered by newly formed anti-pig antibodies, complement deposition, and infiltration by human immune cells. Cell-mediated rejection involves activation of T cells, macrophages, and NK cells that recognize porcine antigens. Advanced immunosuppressive regimens, including costimulation blockade (e.g., anti-CD40 monoclonal antibodies), are being trialed to mitigate these responses. Additionally, depletional induction therapies (e.g., anti-thymocyte globulin) are used to reduce the burden of xenoreactive lymphocytes.

Another key concern is physiologic incompatibility—porcine proteins may not interact effectively with human receptors, affecting coagulation, endothelial function, and cardiac physiology. This has led to the generation of multi-transgenic pigs, which express multiple human genes to better match human physiology.

There is also growing focus on xenozoonosis, or the transmission of animal viruses to humans, especially porcine endogenous retroviruses (PERVs). Although modern genetic editing techniques like CRISPR/Cas9 have been used to inactivate PERVs, the long-term risk of zoonotic infection remains a critical area of surveillance.

In 2022, the first successful pig-to-human heart xenotransplantation was performed under emergency use authorization, marking a milestone in the field. Though the recipient survived for nearly two months, graft failure was ultimately attributed to a combination of immune, infectious, and mechanical factors. This case underscored both the promise and the limitations of current approaches.

Ongoing research aims to improve tolerance induction, possibly through mixed chimerism, regulatory T cell therapies, or immune resetting techniques. Ethical concerns, regulatory frameworks, and public acceptance also shape the future trajectory of xenotransplantation research and implementation.

Conclusion

Porcine-to-human heart xenotransplantation holds transformative potential for addressing the global organ shortage, particularly for patients with terminal heart failure. While significant immunologic hurdles—such as hyperacute rejection, cellular immunity, and compatibility issues—remain, advances in genetic engineering, immunomodulatory strategies, and infection control have brought the field closer to clinical reality. Continued multidisciplinary efforts in transplant immunology, genetics, virology, and bioethics are essential for safe and sustainable progress. With further refinement and regulatory oversight, porcine heart xenotransplantation may soon shift from experimental therapy to a viable clinical option, offering hope to thousands in need.

References

1. Kute VB, Vanikar AV, Patel HV, Shah PR, Gumber MR, et al. (2014) . Ren Fail 36: 1215-1220.

   , ,

2. Rawal N, Yazigi N (2017) . Pediatr Clin North Am 64: 677-684.

   , ,

3. Meirelles Júnior RF, Salvalaggio P, Rezende MBD, Evangelista AS, Guardia BD, et al. (2015) . Einstein 13: 149-152.

   , ,

4. Fox AN, Brown RS (2012) Clin Liver Dis 16: 435-448.

   , ,

5. Kohli R, Cortes M, Heaton ND, Dhawan A (2018) . Arch Dis Child 103: 192-198.

   , ,

6. Samuel D, Coilly A (2018) . BMC Med 16: 1-5.

   , ,

7. Cheng XS, Wall A, Teuteberg J (2020) . Curr Opin Organ Transplant 25: 519-525.

   , ,

8. Gong N, Chen X (2011) . Front Med 5: 1-7.

   , ,

9. Mathurin P (2021) . J Hepatol 75: 718-722.

   , ,

10. Kerkar N, Emre S (2007) . Clin Liver Dis 11: 323-335.

    , ,